Early this morning we announced an initiative to deliver and enhance a minimally invasive circulating tumor DNA (ctDNA) test to cancer patients across Canada in response to COVID-19. Thousands have been adversely affected since the pandemic forced health systems to delay or cancel surgeries including tissue biopsies.

Supported by the Digital Technology Supercluster, Project ACTT – Access to Cancer Testing & Treatment in Response to COVID-19 makes testing immediately available to 2,000 patients with lung, breast, or colorectal cancer in Canada. We are honoured to lead this project in partnership with Queen’s University, AstraZeneca Canada, the Eastern Ontario Regional Laboratory Association, Genolife, Semaphore Solutions, emtelligent, Xtract AI, Novateur, and Illumina. 

Working with this impressive roster, we will also enhance the ctDNA solution to detect a broader range of cancer types, increasing the potential reach from 40,000 to 70,000 cancer patients each year in Canada alone. Further, the project will generate the data required to determine if this testing can be delivered under provincial health coverage — making it possible to conduct tests in-house at Canadian hospitals and labs, increasing availability in remote and rural areas, and future-proofing against COVID-19 and other pandemics. 

Read more about Project ACTT in today’s press release.

Learn more about how to get tested


Today also marks another important milestone for our company.

Over the past year, we have grown our commercial team, welcomed new customers and collaborators, and are on the path to fundamentally change how patients and oncologists gain information about cancer treatment selection. During this time, we have also heard from prospective partners, oncologist groups, and patients that our company name did not fully communicate our expertise beyond genomics. We thus embarked on a journey to identify a corporate name reflective of our work today and our strategic vision for the future.

As of today, our company is now Canexia Health

Canexia Health represents our deep focus on cancer patients, our commitment to exacting knowledge, and the community nexus we are building with partners to make precision oncology affordable and accessible. What has changed? Our name, logo, and visual assets including our newly refreshed website. Our mission remains, and there is no impact on how we operate. 

More to come in the coming weeks on this exciting new chapter. In the meantime, visit us at www.canexiahealth.com.



Recent Resources


September 22, 2020

Why Bring Liquid Biopsy Testing In-House? The Case for Millions in Cost Savings

We recently conducted a cost savings analysis for healthcare organizations interested in bringing liquid biopsy testing in-house. We discovered that, compared to outsourcing, in-house liquid biopsy testing with an actionable circulating tumor DNA (ctDNA) panel would enable healthcare organizations to attain substantial cost savings -- $2.7M per 1,000 cancer patients.

In the News

August 27, 2020

DeciBio’s Q&A with Brady Davis, SVP of Business Development for Canexia Health

DeciBio interviewed Canexia Health's Brady Davis to discuss how Canexia Health and Project ACTT (Access to Testing and Treatment) are leveraging Canexia’s tech transfer platform and liquid biopsy test, Follow IT, to bridge the gap between the Canadian cancer community and molecular testing during the COVID-19 pandemic.